TRON and ByoRNA SAS (“bYoRNA”) announce a research collaboration targeting the production of therapeutic mRNA using eucaryotic cell biofactories to help develop the therapeutic potential of mRNA.

bYoRNA is a French biotechnology company focused on producing affordable and innovative therapeutic mRNA, at scale, for human and animal health. “By leveraging our bYoRNA’s novel eukaryotic mRNA bioproduction platform with TRON’s expertise in therapeutic mRNA design and mRNA sequences, we will be able to develop therapeutic opportunities based on this modality and provide the pharmaceutical industry access to innovative drugs to a broader global population,” said Thierry Ziegler, bYoRNA’s Chief Technology Officer. We look forward to join forces and to contribute with our expertise in therapeutic mRNA design.

To learn more about bYoRNA and its commitment to producing mRNA vaccines visit the following website:  Home | Byorna